Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo.

Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK, Gentry WB, Tong Y.

Clin Pharmacol Ther. 2008 Jan;83(1):61-9.

PMID:
17495878
2.

Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans.

Gurley BJ, Swain A, Barone GW, Williams DK, Breen P, Yates CR, Stuart LB, Hubbard MA, Tong Y, Cheboyina S.

Drug Metab Dispos. 2007 Feb;35(2):240-5.

3.

In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes.

Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A.

Clin Pharmacol Ther. 2005 May;77(5):415-26.

4.

Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea.

Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F, Tong Y, Carrier DJ, Cheboyina S, Battu SK.

Mol Nutr Food Res. 2008 Jul;52(7):755-63. doi: 10.1002/mnfr.200600300.

5.

Midazolam and cortisol metabolism before and after CYP3A induction in humans.

Eeckhoudt SL, Desager JP, Robert AR, Leclercq I, Verbeeck RK, Horsmans Y.

Int J Clin Pharmacol Ther. 2001 Jul;39(7):293-9.

PMID:
11471773
6.

In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies.

Prueksaritanont T, Kuo Y, Tang C, Li C, Qiu Y, Lu B, Strong-Basalyga K, Richards K, Carr B, Lin JH.

Drug Metab Dispos. 2006 Sep;34(9):1546-55.

7.
8.

Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans.

Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY.

Clin Pharmacol Ther. 2002 Sep;72(3):276-87.

PMID:
12235448
9.

Phenotyping studies to assess the effects of phytopharmaceuticals on in vivo activity of main human cytochrome p450 enzymes.

Zadoyan G, Fuhr U.

Planta Med. 2012 Sep;78(13):1428-57. doi: 10.1055/s-0031-1298536. Review.

10.

Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers.

Krupka E, Venisse N, Lafay C, Gendre D, Diquet B, Bouquet S, Perault MC.

Eur J Clin Pharmacol. 2006 Aug;62(8):653-9.

PMID:
16832678
11.

Influence of goldenseal root on the pharmacokinetics of indinavir.

Sandhu RS, Prescilla RP, Simonelli TM, Edwards DJ.

J Clin Pharmacol. 2003 Nov;43(11):1283-8.

PMID:
14551183
12.

Effects of Phyllanthus amarus on the pharmacokinetics of midazolam and cytochrome P450 activities in rats.

Taesotikul T, Nakajima M, Tassaneeyakul W, Yokoi T.

Xenobiotica. 2012 Jul;42(7):641-8. doi: 10.3109/00498254.2012.655703.

PMID:
22339466
13.

Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam.

Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K, Whittington D, Ensign D.

Clin Pharmacol Ther. 2007 Oct;82(4):410-26.

PMID:
17554244
14.

Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin.

Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB, Breen P, Carrier DJ, Cheboyina S.

J Clin Pharmacol. 2006 Feb;46(2):201-13.

15.

Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results.

Chenel M, Bouzom F, Cazade F, Ogungbenro K, Aarons L, Mentré F.

J Pharmacokinet Pharmacodyn. 2008 Dec;35(6):661-81. doi: 10.1007/s10928-008-9105-5.

16.

Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.).

Anke J, Ramzan I.

J Ethnopharmacol. 2004 Aug;93(2-3):153-60. Review.

PMID:
15234747
17.

Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs.

Kuroha M, Azumano A, Kuze Y, Shimoda M, Kokue E.

Drug Metab Dispos. 2002 Jan;30(1):63-8.

19.

Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.

Chien JY, Lucksiri A, Ernest CS 2nd, Gorski JC, Wrighton SA, Hall SD.

Drug Metab Dispos. 2006 Jul;34(7):1208-19.

20.

Supplemental Content

Support Center